Nereus attracts $20M round for cancer drug programs

With its Phase II lung cancer trial fully enrolled, San Diego-based Nereus Pharmaceuticals says that a roster of venture firms has kicked in a $20 million round to back its two cancer programs. The financing was led by HBM BioVentures and included Alta Partners, Forward Ventures, Gimv, Advent International, Pacific Venture Group, Roche Venture Fund, and Astellas Venture Management.   Nereus, which is developing therapies derived from marine microbes, recruited 170 patients for its...